[Clinical characteristics of 111 cases with mucopolysaccharidosis ⅣA].
M N Yi,H W Zhang,X L Gao,Y Wang,L S Han,W J Qiu,X F Gu
DOI: https://doi.org/10.3760/cma.j.cn112140-20230308-00170
2023-01-01
Abstract: To analyze the clinical characteristics of patients with Mucopolysaccharidosis ⅣA (MPS ⅣA). A retrospective study was conducted on 111 patients with MPS ⅣA in Xinhua Hospital of Shanghai Jiao Tong University School of Medcine from December 2008 to August 2020, confirmed by enzyme activity and genetic testing. General situation, clinical manifestations and enzyme activity test results were analyzed. According to the clinical manifestations, it can be divided into severe, intermediate and mild group. The independent sample test was used to compare the birth body length and weight of children with that of normal boys and girls, and group comparisons of enzyme activities were evaluated by median test. One hundred and eleven unrelated patients, 69 males and 42 females, were classified into 3 subtypes: severe (=85), intermediate (=14), and mild (=12). The age at symptom onset were 1.6 (1.0, 3.0) years, and at diagnosis were 4.3 (2.8, 7.8) years. Skeletal manifestations were observed in all patients and consisted mainly of pectus carinatum (96/111, 86.5%), motor dysfunction (78/111, 70.3%), spinal deformity (71/111, 64.0%), growth retardation (64/111, 57.7%), joint laxity (63/111, 56.8%) and genu valgum (62/111, 55.9%). Eighty-eight patients (88/111, 79.3%) with MPS ⅣA were also along with non-skeletal manifestations, mainly including snoring (38/111, 34.2%), coarse faces (34/111, 30.6%), and visual impairment (26/111, 23.4%). The most common skeletal manifestation was pectus carinatum (79 cases), and non-skeletal manifestation was snoring (30 cases) and coarse faces (30 cases) in severe patients, pectus carinatum (13 cases) and snoring (5 cases) in intermediate type, motor dysfunction (11 cases) and snoring (3 cases) and visual impairment (3 cases) in mild patients. The height and weight of severe patients began to fall below -2 at 2-<5 years and 5-<7 years, respectively. At the age of 10-<15 years, the standard deviation score of the height of severe patients reached (-6.2±1.6) in males and (-6.4±1.2) in females, and the score of weight got (-3.0±1.1) in males and (-3.5±0.5) in females. The height of intermediate patients began to fall below -2 at the age of 7-<10 years, and the standard deviation score of height were -4.6 and -3.6 in 2 males, and -4.6 and -3.8 in 2 females at the age of 10-<15 years. The weight remained within -2 in 72.0% (18/25) of intermediate patients compared to age-matched healthy children. In the mild patients with MPS ⅣA, the mean standard deviation score of height and weight was within -2 . The enzyme activities of mild patients (2.02 (1.05, 8.20) nmol/(17 h·mg)) were both significantly higher than that of intermediate (0.57 (0.47, 0.94) nmol/(17 h·mg)) and severe (0.22 (0, 0.59) nmol/(17 h·mg)) patients (=9.91, 13.98, =0.005, 0.001), and the enzyme activity of intermediate patients was significantly higher than that of severe patients (=8.56, =0.010). The clinical manifestations of MPS ⅣA are charactered by pectus carinatum, motor function impairment, spinal deformity and growth retardation. The clinical characteristics, growth rate and enzyme activity differ among the 3 subtypes of MPS ⅣA.